CORONA vs PARASHLTH: Stock Comparison
CORONA REMEDIES is the larger company by market capitalisation. CORONA REMEDIES shows a higher dividend yield and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
CORONA leads 2; PARASHLTH leads 0 of 4
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | CORONA | PARASHLTH |
|---|---|---|
| Live Price | ₹2,441.1 | ₹734.55 |
| Day Change | 2.58% | -5.12% |
| Volume | 1.45 L | 4.08 L |
| 52-Week High | ₹2,458 | ₹794.4 |
| 52-Week Low | ₹1,336.6 | ₹706 |
| Distance from 52W High | -0.69% | -7.53% |
Valuation
| Metric | CORONA | PARASHLTH |
|---|---|---|
| Market Cap | ₹15,290 Cr | ₹7,931 Cr |
| P/E Ratio | 73.86x | — |
| P/B Ratio | 18.99x | — |
| EPS | ₹9.86 | — |
| Book Value | ₹122.12 | — |
| Dividend Yield | 0.4% | 0% |
Growth
| Metric | CORONA | PARASHLTH |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 4.44% | — |
| Qtr Profit Growth | 0.33% | — |
Profitability & Leverage
| Metric | CORONA | PARASHLTH |
|---|---|---|
| ROE | 24.78% | — |
| ROCE | 21.44% | — |
| Net Margin | 13.19% | 0% |
| Operating Margin | 17.61% | — |
| Debt to Equity | 0.19x | — |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | CORONA | PARASHLTH |
|---|---|---|
| Promoter Holding | 69% | — |
| FII Holding | 4.21%▲ 0.58 pp | — |
| DII Holding | 16.45%▲ 3.55 pp | — |
| Public Holding | 10.34%▼ 4.14 pp | — |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: CORONA REMEDIES and PARAS HEALTHCARE.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.